Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM paidMAD0.0 Mil more to buy back shares than it received from issuing new shares.
It receivedMAD0.0 Mil from issuing more debt.
It paidMAD0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMAD0.0 Mil from paying cash dividends to shareholders.
It receivedMAD0.0 Mil on other financial activities.
In all, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARMspentMAD0.0 Mil on financial activities for the
six
months ended in Dec. 2025.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's issuance of stock for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's repurchase of stock for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's net issuance of debt for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM receivedMAD0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's net issuance of preferred for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM paidMAD0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's cash flow for dividends for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM receivedMAD0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's other financing for the
six
months ended in Dec. 2025 was MAD0.0 Mil.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM receivedMAD0.0 Mil on other financial activities.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Cash Flow from Financing Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Cash Flow from Financing Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MAD0.0 Mil mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Cash Flow from Financing of MAD0.0 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Cash Flow from Financing too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Cash Flow from Financing is MAD0.0 Mil. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Cash Flow from Financing compare to ZTS and UTHR?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Cash Flow from Financing of MAD0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Cash Flow from Financing is MAD0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,330.92, compared to a current price of MAD1,349.00 — trading 1.4% above its estimated fair value. The current Cash Flow from Financing is MAD0.0 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Cash Flow from Financing is MAD0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,349.00 is trading 1.4% above its estimated GF Value™ of MAD1,330.92.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
Cash Flow from Financing: MAD0.0 Mil
GF Value™: MAD1,330.92 vs. price of MAD1,349.00 (1.4% above fair value)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
87GF Score
Get the complete analysis for CAS:PRO
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
